Literature DB >> 5538632

Australia antigen in volunteer and paid blood donors.

A Kliman.   

Abstract

Mesh：

Substances：

Year:  1971        PMID： 5538632

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  8 in total

1.  Prevention of viral hepatitis.

Authors:  G F Grady
Journal:  Can Med Assoc J       Date:  1972-02-26       Impact factor: 8.262

2.  Incidence of hepatitis B in the penitentiary of New Mexico.

Authors:  H F Hull; L H Lyons; J M Mann; S C Hadler; R Steece; M R Skeels
Journal:  Am J Public Health       Date:  1985-10       Impact factor: 9.308

3.  Liver disease and cell-mediated immunity in hepatitis-associated antigen (HAA) carriers.

Authors:  T D Bolin; A E Davis; A G Liddelow
Journal:  Gut       Date:  1973-05       Impact factor: 23.059

4.  [The characterization of clinically healthy hepatitis-b-surface-antigen (HBsAg)-carriers. Clinical, biochemical, histiological and immunological investigations in 129 case of a prospective study (author's transl)].

Authors:  J Knolle; M Born; G Hess; O Klinge; W Arnold; H Bitz; K H Meyer
Journal:  Klin Wochenschr       Date:  1976-06-15

5.  Hepatitis B virus infection in prisons. A seroepidemiological survey in prisoners and attending staff.

Authors:  M Chiaramonte; R Trivello; G Renzulli; L Zampieri; A Fanecco; A Floreani; R Naccarato
Journal:  J Hyg (Lond)       Date:  1982-08

6.  Prevalence of liver disease and infection by hepatitis B, delta virus, and human immunodeficiency virus in two Spanish penitentiaries.

Authors:  J A del Olmo; F Llovet; J M Rodrigo; J Molina; L Aparisi; M A Serra; A Wassel; M A Bixquert
Journal:  Med Microbiol Immunol       Date:  1990       Impact factor: 3.402

7.  Hepatitis B in Wisconsin male prisoners: considerations for serologic screening and vaccination.

Authors:  R F Anda; S B Perlman; D J D'Alessio; J P Davis; V N Dodson
Journal:  Am J Public Health       Date:  1985-10       Impact factor: 9.308

Review 8.  Ensuring the biologic safety of plasma-derived therapeutic proteins: detection, inactivation, and removal of pathogens.

Authors:  Kang Cai; Todd M Gierman; JoAnn Hotta; Christopher J Stenland; Douglas C Lee; Dominique Y Pifat; Steve R Petteway
Journal:  BioDrugs       Date:  2005       Impact factor: 5.807
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.